|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Noordhuis MG, Eijsink JJH, Roossink F, de
Graeff P, Pras E, Schuuring E, Wisman GB, de Bock GH and van der
Zee AG: Prognostic cell biological markers in cervical cancer
patients primarily treated with (chemo)radiation: A systematic
review. Int J Radiat Oncol Biol Phys. 79:325–334. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Downs L: Advances in cervical cancer
treatment. Gynecol Oncol. 121:431–433. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fujiwara M, Isohashi F, Mabuchi S,
Yoshioka Y, Seo Y, Suzuki O, Sumida I, Hayashi K, Kimura T and
Ogawa K: Efficacy and safety of nedaplatin-based concurrent
chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its
clinical prognostic factors. J Radiat Res. 56:305–314. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tangjitgamol S, Katanyoo K, Laopaiboon M,
Lumbiganon P, Manusirivithaya S and Supawattanabodee B: Adjuvant
chemotherapy after concurrent chemoradiation for locally advanced
cervical cancer. Cochrane Database Syst Rev. 3:CD0104012014.
|
|
6
|
Hosoya N and Miyagawa K: Targeting DNA
damage response in cancer therapy. Cancer Sci. 105:370–388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bajinskis A, Natarajan AT, Erixon K and
Harms-Ringdahl M: DNA double strand breaks induced by the indirect
effect of radiation are more efficiently repaired by non-homologous
end joining compared to homologous recombination repair. Mutat Res.
756:21–29. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goldstein M and Kastan MB: The DNA damage
response: Implications for tumor responses to radiation and
chemotherapy. Annu Rev Med. 66:129–143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Khan KH, Blanco-Codesido M and Molife LR:
Cancer therapeutics: Targeting the apoptotic pathway. Crit Rev
Oncol Hematol. 90:200–219. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jekimovs C, Bolderson E, Suraweera A,
Adams M, O'Byrne KJ and Richard DJ: Chemotherapeutic compounds
targeting the DNA double-strand break repair pathways: The good,
the bad and the promising. Front Oncol. 4:862014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Basu A and Krishnamurthy S: Cellular
responses to Cisplatin-induced DNA damage. J nucleic acids.
2010:2013672010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou X, Gu Y and Zhang SL: Association
between p53 codon 72 polymorphism and cervical cancer risk among
Asians: A huge review and meta-analysis. Asian Pac J Cancer Prev.
13:4909–4914. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sionov RV and Haupt Y: The cellular
response to p53: The decision between life and death. Oncogene.
18:6145–6157. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Naccarati A, Polakova V, Pardini B,
Vodickova L, Hemminki K, Kumar R and Vodicka P: Mutations and
polymorphisms in TP53 gene-an overview on the role in colorectal
cancer. Mutagenesis. 27:211–218. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Golubovskaya VM and Cance WG: Targeting
the p53 pathway. Surg Oncol Clin N Am. 22:747–764. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dos Santos HG, Nunez-Castilla J and
Siltberg-Liberles J: Functional diversification after gene
duplication: Paralog specific regions of structural disorder and
phosphorylation in p53, p63 and p73. PLoS One. 11:e01519612016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Donehower LA: p53: Guardian and suppressor
of longevity? Exp Gerontol. 40:7–9. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Haupt S, Raghu D and Haupt Y: Mutant p53
drives cancer by subverting multiple tumor suppression pathways.
Front Oncol. 6:122016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu J, Zhang C and Feng Z: Tumor
suppressor p53 and its gain-of-function mutants in cancer. Acta
biochim biophys Sin (Shanghai). 46:170–179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dastjerdi MN: TP53 codon 72 polymorphism
and P53 protein expression in colorectal cancer specimens in
Isfahan. Acta Med Iran. 49:71–77. 2011.PubMed/NCBI
|
|
21
|
Hu X, Zhang Z, Ma D, Huettner PC, Massad
LS, Nguyen L, Borecki I and Rader JS: TP53, MDM2, NQO1 and
susceptibility to cervical cancer. Cancer Epidemiol Biomarkers
Prev. 19:755–761. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Santos AM, Sousa H, Catarino R, Pinto D,
Pereira D, Vasconcelos A, Matos A, Lopes C and Medeiros R: TP53
codon 72 polymorphism and risk for cervical cancer in Portugal.
Cancer Genet Cytogenet. 159:143–147. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dokianakis DN and Spandidos DA: P53 codon
72 polymorphism as a risk factor in the development of
HPV-associated cervical cancer. Mol Cell Biol Res Commun.
3:111–114. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sousa H, Santos AM, Pinto D and Medeiros
R: Is there a biological plausability for p53 codon 72 polymorphism
influence on cervical cancer development? Acta Med Port.
24:127–134. 2011.PubMed/NCBI
|
|
25
|
Hrstka R, Coates PJ and Vojtesek B:
Polymorphisms in p53 and the p53 pathway: Roles in cancer
susceptibility and response to treatment. J Cell Mol Med.
13:440–453. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dahabreh IJ, Schmid CH, Lau J, Varvarigou
V, Murray S and Trikalinos TA: Genotype misclassification in
genetic association studies of the rs1042522 TP53 (Arg72Pro)
polymorphism: A systematic review of studies of breast, lung,
colorectal, ovarian and endometrial cancer. Am J Epidemiol.
177:1317–1325. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bojesen SE and Nordestgaard BG: The common
germline Arg72Pro polymorphism of p53 and increased longevity in
humans. Cell Cycle. 7:158–163. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bergamaschi D, Gasco M, Hiller L, Sullivan
A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, et
al: p53 polymorphism influences response in cancer chemotherapy via
modulation of p73-dependent apoptosis. Cancer Cell. 3:387–402.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu JH, Xi P, Chai YL, Wang J, Wang T, Liu
Z and Dai PG: Association of DNA repair gene polymorphisms with
response to cisplatin-based concurrent chemoradiotherapy in
patients with cervical carcinoma. DNA Repair (Amst). 41:69–72.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Piña-Sánchez P, Hernández-Hernández DM,
Taja-Chayeb L, Cerda-Flores RM, González-Herrera AL, Rodea-Avila C,
Apresa-García T, Ostrosky-Wegman P, Vázquez-Ortíz G,
Mendoza-Lorenzo P, et al: Polymorphism in exon 4 of TP53 gene
associated to HPV 16 and 18 in Mexican women with cervical cancer.
Med Oncol. 28:1507–1513. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sousa H, Santos AM, Pinto D and Medeiros
R: Is the p53 codon 72 polymorphism a key biomarker for cervical
cancer development? A meta-analysis review within European
populations. Int J Mol Med. 20:731–741. 2007.PubMed/NCBI
|
|
33
|
Papadakis ED, Soulitzis N and Spandidos
DA: Association of p53 codon 72 polymorphism with advanced lung
cancer: The Arg allele is preferentially retained in tumours
arising in Arg/Pro germline heterozygotes. Br J Cancer.
87:1013–1018. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hollingworth R and Grand RJ: Modulation of
DNA damage and repair pathways by human tumour viruses. Viruses.
7:2542–2591. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rassool FV and Tomkinson AE: Targeting
abnormal DNA double strand break repair in cancer. Cell Mol Life
Sci. 67:3699–3710. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: A link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Martinez-Rivera M and Siddik ZH:
Resistance and gain-of-resistance phenotypes in cancers harboring
wild-type p53. Biochem Pharmacol. 83:1049–1062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Petitjean A, Achatz MI, Borresen-Dale AL,
Hainaut P and Olivier M: TP53 mutations in human cancers:
Functional selection and impact on cancer prognosis and outcomes.
Oncogene. 26:2157–2165. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Medeiros R, Prazeres H, Pinto D,
Macedo-Pinto I, Lacerda M, Lopes C and Cruz E: Characterization of
HPV genotype profile in squamous cervical lesions in Portugal, a
southern European population at high risk of cervical cancer. Eur J
Cancer Prev. 14:467–471. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dong M, Nio Y, Yamasawa K, Toga T, Yue L
and Harada T: p53 alteration is not an independent prognostic
indicator, but affects the efficacy of adjuvant chemotherapy in
human pancreatic cancer. J Surg Oncol. 82:111–120. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wu WJ, Kakehi Y, Habuchi T, Kinoshita H,
Ogawa O, Terachi T, Huang CH, Chiang CP and Yoshida O: Allelic
frequency of p53 gene codon 72 polymorphism in urologic cancers.
Jpn J Cancer Res. 86:730–736. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang YC, Chen CY, Chen SK, Chang YY and
Lin P: p53 codon 72 polymorphism in Taiwanese lung cancer patients:
Association with lung cancer susceptibility and prognosis. Clin
Cancer Res. 5:129–134. 1999.PubMed/NCBI
|
|
43
|
Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan
Z, Lin B, Lu Y and Xie Y: p53 Codon 72 polymorphism predicts the
pathologic response to neoadjuvant chemotherapy in patients with
breast cancer. Clin Cancer Res. 11:7328–7333. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sullivan A, Syed N, Gasco M, Bergamaschi
D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X and
Crook T: Polymorphism in wild-type p53 modulates response to
chemotherapy in vitro and in vivo. Oncogene. 23:3328–3337. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tommiska J, Eerola H, Heinonen M, Salonen
L, Kaare M, Tallila J, Ristimäki A, von Smitten K, Aittomäki K,
Heikkilä P, et al: Breast cancer patients with p53 Pro72 homozygous
genotype have a poorer survival. Clin Cancer Res. 11:5098–5103.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Starinsky S, Figer A, Ben-Asher E, Geva R,
Flex D, Fidder HH, Zidan J, Lancet D and Friedman E: Genotype
phenotype correlations in Israeli colorectal cancer patients. Int J
Cancer. 114:58–73. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pietsch EC, Humbey O and Murphy ME:
Polymorphisms in the p53 pathway. Oncogene. 25:1602–1611. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bonafé M, Ceccarelli C, Farabegoli F,
Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G,
Olivieri F and Franceschi C: Retention of the p53 codon 72 arginine
allele is associated with a reduction of disease-free and overall
survival in arginine/proline heterozygous breast cancer patients.
Clin Cancer Res. 9:4860–4864. 2003.PubMed/NCBI
|
|
49
|
Storey A, Thomas M, Kalita A, Harwood C,
Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G and
Banks L: Role of a p53 polymorphism in the development of human
papillomavirus-associated cancer. Nature. 393:229–234. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chansaenroj J, Theamboonlers A,
Junyangdikul P, Swangvaree S, Karalak A, Chinchai T and Poovorawan
Y: Polymorphisms in TP53 (rs1042522), p16 (rs11515 and rs3088440)
and NQO1 (rs1800566) genes in thai cervical cancer patients with
HPV 16 infection. Asian Pac J Cancer Prev. 14:341–346. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Santos AM, Sousa H, Pinto D, Portela C,
Pereira D, Catarino R, Duarte I, Lopes C and Medeiros R: Linking
TP53 codon 72 and P21 nt590 genotypes to the development of
cervical and ovarian cancer. Eur J Cancer. 42:958–963. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Peralta-Zaragoza O, Bermúdez-Morales VH,
Pérez-Plasencia C, Salazar-León J, Gómez-Cerón C and Madrid-Marina
V: Targeted treatments for cervical cancer: A review. Onco Targets
Ther. 5:315–328. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wallace NA and Galloway DA: Manipulation
of cellular DNA damage repair machinery facilitates propagation of
human papillomaviruses. Semin Cancer Biol. 26:30–42. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Schneider-Stock R, Mawrin C, Motsch C,
Boltze C, Peters B, Hartig R, Buhtz P, Giers A, Rohrbeck A,
Freigang B and Roessner A: Retention of the arginine allele in
codon 72 of the p53 gene correlates with poor apoptosis in head and
neck cancer. Am J Pathol. 164:1233–1241. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Matakidou A, El Galta R, Webb EL, Rudd MF,
Bridle H, Eisen T and Houlston RS: GELCAPS Consortium: Lack of
evidence that p53 Arg72Pro influences lung cancer prognosis: An
analysis of survival in 619 female patients. Lung Cancer.
57:207–212. 2007. View Article : Google Scholar : PubMed/NCBI
|
